Using antidepressants during the second or third trimester is associated with an increased risk of autism spectrum diseases (ASD), according to a new study from Canada.
The study included 1,054 children with ASD aged, on average, 6.2 years at the end of follow-up. Boys outnumbered girls by about 4:1. After adjusting for potential con-founders, the 31 offspring of mothers who took antidepressants during the second or third trimester or both were found to be 87 per cent more likely to have ASD than those who were not exposed to antidepressants.
Taking selective serotonin reuptake inhibitors (SSRIs) during the second or third trimester or both doubled the risk of ASD (hazard ratio 2.17) overall and after controlling for maternal history of depression (hazard ratio 1.75).
The association seems biologically plausible. SSRIs can cross the placenta and serotonin modulates numerous developmental processes, including cell division, neuronal migration, cell differentiation and synaptogenesis. (JAMA Pediatr doi: 10.1001/ jamapediatrics.2015.3356)
A UK study has reported a link between antidepressants and mania or bipolar disorder. See BMJ Open 2015;5:e008341.
This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.
We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.
